LivoClear corrects liver damage and clears fatty infiltration and inflammation of the liver due to metabolic syndrome and obesity, or toxins such as alcohol. A large randomized control trial has shown that this formula reduces fatty infiltrate in the liver on a histological level, normalising liver enzymes AST, ALT and GGT. Further trials have also demonstrated significant hepatoprotective effects against paracetamol, CCL4, aflotoxin and ethanol-induced liver damage. LivoClear also reduces liver inflammation associated with Hepatitis B infection and reduces viral load. Several studies have demonstrated that LivoClear in the correct dosage is an effective treatment for both acute and chronic Hepatitis B.
LivoClear is an essential co-prescription to conventional Hepatotoxic drugs, including certain antibiotics, hypoglycaemics, analgesics, tuberculosis treatment and anti-retrovirals.